(Alliance News) - Ondine Biomedical Inc on Thursday said by introducing its Steriwave product into the intensive care unit market could expand its revenue potential.

Shares in Ondine Biomedical fell 8.1% to 8.50 pence each in London on Thursday afternoon.

The Vancouver-based life sciences company said that a 2012 study involving nearly 75,000 patients across 74 adult ICUs, demonstrated the effectiveness of daily nasal decolonisation for patients in ICUs.

Steriwave, which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues, is already used in hospitals across Canada to reduce healthcare-associated infection in patients undergoing surgery.

Ondine Biomedical believes that a move into the routine treatment of highly compromised patients in ICUs has the potential to "significantly expand Steriwave usage in hospitals", boosting sales.

Ondine has regulatory approvals in Canada, Mexico, the UK, and Europe that cover using Steriwave in the ICU.

Chief Executive Officer Carolyn Cross commented: "We have long known that the ICU is an epicenter of hospital infection due to the vulnerable population of critically ill patients and the high use of invasive procedures including intubation, catheters and ports. We believe that Steriwave can offer a far more effective solution to ICU infections than nasal antibiotics, and we are looking forward to capitalising on this large market segment. Ondine will be able to reach ICUs using its existing sales and marketing infrastructure, making this an obvious area for us to expand into."

Just last month, Ondine reported significant commercial progress to date in 2024, ahead of its expectations, with its Steriwave technology deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.